Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Mar 1;128(3):900-902.
doi: 10.1172/JCI99725. Epub 2018 Jan 29.

Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia: the buck stops here?

Affiliations
Comment

Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia: the buck stops here?

Juan A Rodriguez et al. J Clin Invest. .

Abstract

Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this site-selective gene deletion raises several questions.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Comment on

References

    1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14(1):10–26. doi: 10.1038/gim.0b013e31822bead0. - DOI - PubMed
    1. de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94(4):1274–1280. doi: 10.1210/jc.2008-1844. - DOI - PubMed
    1. Shim JS, Lee SH, Seo SW, Koo KH, Jin DK. The musculoskeletal manifestations of Prader-Willi syndrome. J Pediatr Orthop. 2010;30(4):390–395. doi: 10.1097/BPO.0b013e3181da857d. - DOI - PubMed
    1. Sinnema M, et al. Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil. 2011;32(5):1729–1735. doi: 10.1016/j.ridd.2011.02.027. - DOI - PubMed
    1. Skokauskas N, Sweeny E, Meehan J, Gallagher L. Mental health problems in children with Prader-Willi syndrome. J Can Acad Child Adolesc Psychiatry. 2012;21(3):194–203. - PMC - PubMed

Publication types

Substances